N-Trans-Feruloyl Tyramine

N-Trans-Feruloyl Tyramine

SCHEMBL17693085

COc1cc(/C=C\C(=O)NCCc2ccc(O)cc2)ccc1O

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 2/20 0.83
ACHE P22303 2/20 0.83
CNR2 P34972 2/20 0.71
MAOA P21397 2/20 0.69
MAOB P27338 2/20 0.69
MET P08581 2/20 0.67
BCHE P06276 1/20 0.67
CA12 O43570 1/20 0.67
CA4 P22748 1/20 0.67
CA6 P23280 1/20 0.67
HTR7 P34969 1/20 0.67
CA5A P35218 1/20 0.67
CA7 P43166 1/20 0.67
CA9 Q16790 1/20 0.67
CA14 Q9ULX7 1/20 0.67
CA5B Q9Y2D0 1/20 0.67
HDAC1 Q13547 1/20 0.67
HDAC6 Q9UBN7 1/20 0.67
ABCB1 P08183 1/20 0.66
AKR1B1 P15121 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
N-Trans-Feruloyl Tyramine SCHEMBL2378679 1.00 TYR (0.83) TYRACHECNR2MAOAMAOB
N-Trans-Feruloyl Tyramine SCHEMBL1675910 1.00 TYR (0.83) TYRACHECNR2MAOAMAOB
N-Trans-Feruloyl Tyramine SCHEMBL29477339 1.00 TYR (0.83) TYRACHECNR2MAOAMAOB
N-Trans-Feruloyl Tyramine SCHEMBL30069091 1.00 TYR (0.83) TYRACHECNR2MAOAMAOB
SCHEMBL17327985 0.93 TYR (0.78) TYRACHECNR2MAOAMAOB
SCHEMBL802998 0.93 ACHE (0.79) TYRACHEMAOAMAOBBCHE
SCHEMBL4812187 0.93 TYR (0.91) TYRACHEMAOAMAOBMET
SCHEMBL1842826 0.93 TYR (0.91) TYRACHEMAOAMAOBMET
SCHEMBL31252895 0.93 TYR (0.91) TYRACHEMAOAMAOBMET
SCHEMBL1917145 0.93 TYR (0.91) TYRACHEMAOAMAOBMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114146104-A Anti-inflammatory active extract of achyranthes aspera 湖南时代阳光药业股份有限公司 2022-03-08 CN claimed
CN-110613741-B Anti-inflammatory active extract of achyranthes aspera and preparation method thereof 湖南时代阳光药业股份有限公司 2022-02-01 CN claimed
CN-120858857-B Application of N-cis feruloyl tyramine in improving rice alkali stress tolerance 三亚市国家耐盐碱水稻技术创新中心 2026-01-06 CN disclosed
CN-120858857-A Application of N-cis feruloyl tyramine in improving rice alkali stress tolerance 三亚市国家耐盐碱水稻技术创新中心 2025-10-31 CN disclosed
EP-4590287-A1 COMPOSITIONS AND METHODS FOR IMPROVING GUT PERMEABILITY Brightseed, Inc. (US) 2025-07-30 EP disclosed
CN-114306550-B Traditional Chinese medicine formula for regulating and controlling intestinal functions of perimenopausal women 刘敏如女科医系研究院(深圳)有限公司 2024-09-17 CN disclosed
WO-2024064102-A1 COMPOSITIONS AND METHODS FOR IMPROVING GUT PERMEABILITY BRIGHTSEED, INC. (US) 2024-03-28 WO disclosed
WO-2023287620-A9 METHODS FOR TREATING CORONAVIRUS INFECTION RABINOFF MICHAEL (US) 2023-11-30 WO disclosed
US-20230354864-A1 EXTRACT, CONSUMABLE PRODUCT AND METHOD FOR ENRICHING BIOACTIVE METABOLITE IN AN EXTRACT BRIGHTSEED, INC. 2023-11-09 US disclosed
US-20230354864-A1 EXTRACT, CONSUMABLE PRODUCT AND METHOD FOR ENRICHING BIOACTIVE METABOLITE IN AN EXTRACT BRIGHTSEED, INC. 2023-11-09 US disclosed
US-20230270699-A1 METHOD FOR MODULATING METABOLISM Sanford Burnham Prebys Medical Discovery Institute 2023-08-31 US disclosed
US-20170105975-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF IONS PHARMACEUTICAL S.À R.L. (LU) 2017-04-20 US disclosed
US-20170042865-A1 THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF IONS PHARMACEUTICAL S.À R.L. (LU) 2017-02-16 US disclosed
US-20170042867-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF IONS PHARMACEUTICAL S.À R.L. (LU) 2017-02-16 US disclosed
US-20170042866-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF IONS PHARMACEUTICAL S.À R.L. (LU) 2017-02-16 US disclosed
US-9402834-B2 Human therapeutic agents IONS PHARMACEUTICAL S.À R.L. (LU) 2016-08-02 US disclosed
US-20160106687-A1 HUMAN THERAPEUTIC AGENTS IONS PHARMACEUTICAL S.À R.L. (LU) 2016-04-21 US disclosed
US-20160106724-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2016-04-21 US disclosed
US-20160106721-A1 HUMAN THERAPEUTIC AGENTS IONS PHARMACEUTICAL S.À R.L. (LU) 2016-04-21 US disclosed
US-20160106722-A1 HUMAN THERAPEUTIC AGENTS IONS PHARMACEUTICAL S.À R.L. (LU) 2016-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230354864-A1 EXTRACT, CONSUMABLE PRODUCT AND METHOD FOR ENRICHING BIOACTIVE METABOLITE IN AN EXTRACT HCAR2, HNMT, TYR TYR 3/4885ACHE 370/4885CNR2 612/4885
US-20230270699-A1 METHOD FOR MODULATING METABOLISM GOT2, GYS2, PC TYR 1959/4885ACHE 1275/4885CNR2 1156/4885
US-20170042865-A1 THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF INMT, HNMT, CPT1A TYR 84/4885ACHE 478/4885CNR2 654/4885
US-20170042867-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF INMT, HNMT, COMT TYR 51/4885ACHE 605/4885CNR2 280/4885
US-20170042866-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF INMT, HNMT, COMT TYR 51/4885ACHE 605/4885CNR2 280/4885
US-20160106722-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN TYR 189/4885ACHE 2039/4885CNR2 586/4885
US-20170105975-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF INMT, HNMT, COMT TYR 51/4885ACHE 605/4885CNR2 280/4885
US-20160106721-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN TYR 189/4885ACHE 2039/4885CNR2 586/4885
US-20160106724-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN TYR 189/4885ACHE 2039/4885CNR2 586/4885
US-20160106687-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN TYR 189/4885ACHE 2039/4885CNR2 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.